Want to see IN:VENUSREM full AI Analyst Report?
Top Page
Venus Remedies Limited
(VENUSREM)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹1,892.00
▲(14.62% Upside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by improving financial performance (sharp profitability and cash-flow step-up in 2026 alongside low leverage). Technicals are supportive with the stock trading above key longer-term averages, though momentum is neutral. Valuation is reasonable but not compelling given a moderate P/E and low dividend yield.
Positive Factors
Revenue growth recovery
The return to positive revenue growth across the latest three years indicates renewed demand and improved commercial execution. Continued top-line expansion can support operating scale, strengthen the company’s market position, and provide a durable base for future earnings growth.
Negative Factors
Limited margin visibility
The absence of current margin data makes it difficult to determine how much of the 2026 earnings surge reflects durable operating improvement versus changes in product mix or cost performance. This uncertainty reduces confidence in forecasting sustainable profitability over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth recovery
The return to positive revenue growth across the latest three years indicates renewed demand and improved commercial execution. Continued top-line expansion can support operating scale, strengthen the company’s market position, and provide a durable base for future earnings growth.
Read all positive factors
Venus Remedies Limited (VENUSREM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹22.11B
Dividend Yield0.62%
Average Volume (3M)2.97K
Price to Earnings (P/E)18.7
Beta (1Y)0.78
Revenue Growth20.87%
EPS Growth116.29%
CountryIN
Employees1,472
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)86.91
Shares Outstanding13,366,988
10 Day Avg. Volume2,807
30 Day Avg. Volume2,972
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.65
Price to Sales (P/S)1.42
P/FCF Ratio9.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.9
Revenue Forecast (FY)₹828.20M
Venus Remedies Limited Business Overview & Revenue Model
Company Description
Venus Remedies Limited is a pharmaceutical enterprise engaged in the development, production, and global distribution of its medicinal products, serving both the Indian and international markets. The company's diverse portfolio addresses a wide sp...
How the Company Makes Money
Venus Remedies primarily makes money by selling pharmaceutical products, with revenue largely derived from the sale of finished dosage formulations (notably hospital/critical-care focused products and injectables, where disclosed) to institutional...
Venus Remedies Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
85
Very Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.11B | 7.70B | 6.48B | 5.91B | 5.56B | 5.99B |
| Gross Profit | 3.25B | 2.68B | 1.66B | 2.18B | 2.25B | 2.00B |
| EBITDA | 1.75B | 1.60B | 944.10M | 711.80M | 703.46M | 701.40M |
| Net Income | 1.16B | 1.03B | 453.20M | 284.91M | 265.70M | 407.24M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 8.54B | 7.16B | 6.27B | 6.01B | 5.80B |
| Cash, Cash Equivalents and Short-Term Investments | 1.03B | 1.04B | 1.64B | 838.05M | 720.77M | 432.56M |
| Total Debt | 0.00 | 124.10M | 16.90M | 413.25M | 422.90M | 428.45M |
| Total Liabilities | -6.64B | 1.90B | 1.55B | 1.39B | 1.41B | 1.39B |
| Stockholders Equity | 6.64B | 6.64B | 5.61B | 4.88B | 4.60B | 4.40B |
Cash Flow | ||||||
| Free Cash Flow | 682.20M | 1.20B | 812.90M | 278.40M | 288.02M | 272.94M |
| Operating Cash Flow | 811.10M | 1.57B | 909.20M | 372.85M | 366.20M | 410.01M |
| Investing Cash Flow | -1.27B | -1.84B | -807.90M | -72.09M | -508.30M | -166.26M |
| Financing Cash Flow | 126.70M | -25.30M | -9.50M | -10.83M | -5.70M | -94.77M |
Venus Remedies Limited Technical Analysis
Negative
1650.60
Price Trends
1671.00
Negative
1498.85
Positive
1143.20
Positive
Market Momentum
-4.64
Positive
46.79
Neutral
36.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VENUSREM, the sentiment is Negative. The current price of 1650.6 is below the 20-day moving average (MA) of 1685.51, below the 50-day MA of 1671.00, and above the 200-day MA of 1143.20, indicating a neutral trend. The MACD of -4.64 indicates Positive momentum. The RSI at 46.79 is Neutral, neither overbought nor oversold. The STOCH value of 36.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VENUSREM.
Venus Remedies Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹12.79B | 13.17 | ― | 0.29% | 10.20% | 11.70% | |
74 Outperform | ₹22.11B | 18.69 | ― | 0.62% | 20.87% | 116.29% | |
70 Outperform | ₹18.94B | 21.16 | ― | 0.51% | 0.44% | 48.60% | |
70 Outperform | ₹23.62B | 35.59 | ― | 0.56% | 18.53% | 1.89% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹33.76B | 55.35 | ― | 1.14% | 113.34% | -80.12% | |
46 Neutral | ₹21.34B | 876.72 | ― | 0.08% | 12.08% | ― |
* General Sector Average
IN:VENUSREM
Venus Remedies Limited
1,632.25
1,182.40
262.84%
IN:INDOCO
Indoco Remedies Limited
263.30
-35.24
-11.80%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
386.10
278.84
259.97%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
625.05
72.92
13.21%
IN:SYNCOMF
Syncom Formulation (India) Ltd.
19.51
1.53
8.51%
IN:WINDLAS
Windlas Biotech Ltd.
1,136.70
149.26
15.12%
Venus Remedies Limited Corporate Events
Venus Remedies Secures Shareholder Approval for All Resolutions at 37th AGM
Aug 21, 2026
Venus Remedies Limited has announced that all 12 resolutions proposed at its 37th Annual General Meeting, held on August 20, 2026 via video conferencing, were approved by the requisite majority under SEBI listing regulations and the Companies Act....
Venus Remedies Publishes 37th AGM Notice in Compliance Filing
Jul 27, 2026
Venus Remedies Limited has notified the stock exchange that it has published the notice for its 37th Annual General Meeting in newspapers in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements. The disclosure ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.